Ophthalmology Therapeutics Market to Amount to USD 35 Bn by 2023, Expects GBI Research in Its In-Demand Report Now Available at MarketPublishers.com
26 Sep 2017 • by Natalie Aster
LONDON – Ophthalmology is a vast therapy filed encompassing around 100 disorders associated with visual system and eyes, including diseases as dry eye syndrome, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, glaucoma, to name a few. Many of eye diseases are progressive in nature, and if left untreated could cause severe visual impairment and even blindness.
The patent of the 3 most commercially successful products are to expire in the year ahead: Avastin (Bevacizumab) and Lucentis (ranibizumab) in 2018, Eylea (aflibercept) in 2020. Still, the revenues generated from the expected new approvals like lampalizumab, Fovista (pegpleranib sodium) and brolucizumab are forecast to exceed the revenue lost as a result of the patent expiry of the current market leaders. Presently, the ophthalmology drugs pipeline includes more than 800 products.
The world’s ophthalmology therapeutics market is predicted to witness stable uptake in the offing and reach the value of around USD 35 billion by the year 2023.
In the short run, top biotech companies will likely lose market share to specialty ophthalmology companies, which are much more active in the pipeline.
In-demand research report “Global Ophthalmology Drugs Market to 2023 - Angiogenesis Inhibitors in wAMD Set to Retain High Market Share, While Expansive Pipeline for Glaucoma Leads the Research Landscape” elaborated by GBI Research gives a comprehensive analysis of the commercial and clinical landscape of the world’s ophthalmology therapeutics market. It examines the current scenario and dynamics with a look at the key influencing factors, presents an insightful overview of the overall pipeline, touches upon the competitive environment and the leading market participants. This study outlines emerging trends and future possible changes and growth opportunities, discusses the major challenges and includes and all-round future outlook for the ophthalmology therapeutics market development up till 2023, etc.
A full collection of the publisher’s research studies is at hand in the GBI Research catalogue at MarketPublishers.com.